I. MODIFIED AGREEMENTS | |||
Company* (Country; Symbol) |
Company | Type/Product Area | Terms/Details (Date) |
ActiveSight* | Lexicon Genetics Inc. (LEXG) | ActiveSight will provide crystallography services for multiple Lexicon targets | The expanded deal is the third between the companies; terms were not disclosed (1/5) |
Diosynth Biotechnology* |
PDL BioPharma Inc. (PDLI) | Extended exclusive agreement for the commercial manufacture of Retavase (reteplase), a fibrinolytic agent that has been marketed in North America for the management of acute myocardial infarction | Financial terms were not disclosed (2/8) |
DSM Biologics (unit of DSM Pharmaceuticals) |
Crucell NV (the Netherlands; CRXL) | Expanded their agreement to include new classes of proteins, including biosimilar protein products | DSM paid Crucell an undisclosed amount in exchange for additional license rights and a higher share of future licensing income (2/8) |
Durect Corp. (DRRX) |
Voyager Pharmaceutical Corp.* | Amended development and commercialization agreement related to Memryte for Alzheimer's disease | Durect will receive a royalty rate ranging from 10% to 14% of net sales, double the original amount, and also would receive 10% of any up-front, milestone and other fees received by Voyager if it sublicenses the product; in return, Durect will pay Voyager $1M and forgive about $725,000 that was owed (1/24) |
Galapagos NV (Belgium; Euronext:GLPG) |
Amgen Inc. (AMGN) | They extended and expanded drug discovery deal from 2003 through 2008; it now includes all targets, and Galapagos' compound collection | The original deal was specific to ion channel targets; Galapagos gets $2.4M up front, and is eligible to receive library and technology-access fees, research fees, milestone payments and bonuses (1/3) |
Idaho Technology Inc.* |
Cepheid inc. (CPHD) | They entered a settlement and cross-license agreement to resolve a dispute related PCR technologies | Cepheid made a one-time payment to Idaho of $3.35M under the deal, which resolves all claims under a lawsuit Idaho filed (1/11) |
MaxCyte Inc.* |
Geron Corp. (GERN) |
Geron exercised an option for a clinical and commercial license to use MaxCyte's cell loading system in the manufacture of mRNA- loaded autologous dendritic cell-based vaccines | Agreement provides Geron with access to the technology to manufacture GRNVAC1 telomerase vaccine and future therapeutic cancer vaccine products; original deal was formed in February 2006 (1/22) |
Micromet Inc. (MITI) |
Morphotek Inc.* | Morphotek exercised its option under a 2004 agreement to obtain an exclusive, worldwide license to an antibody targeting an antigen with potential activity for treating certain cancers | Micromet received a payment for the option exercise, and is eligible to receive development milestone payments and royalties on sales (2/12) |
MorphoSys AG (Germany; FSE:MOR) |
GeneFrontier Corp.* (Japan) | Expanded marketing deal to cover generation of HuCAL- derived fully human antibodies for proteome research and target validation | GeneFrontier will use MorphoSys' HuCAL Gold antibody library to generate anti- bodies against targets provided by the partner; MorphoSys gets undisclosed compensation for access to its technology (1/26) |
Transgenomic Inc. (TBIO) |
Fiuotecnica Srl (Italy) | Renewed collaboration for production and marketing of a genetic panel assay to predict the risk of cardiovascular disease and heart attacks | The effort uses Transgenomic's WAVE System; Fiuotecnica has marketing rights in Italy, while Transgenomic will have rights in the rest of the world (2/6) |
II. TERMINATED AGREEMENTS | |||
Company* (Country; Symbol) |
Company | Type/Product Area | Terms/Details (Date) |
Cytogen Corp. (CYTO) |
Advanced Magnetics Inc. (FSE:AMU) | Terminated their 10-year license, marketing and supply agreement established in August 2000 for two cancer-related imaging agents, Combidex and ferumoxytol | Companies settled their lawsuit and Advanced Magnetics agreed to pay $4M to Cytogen and release 50,000 shares of Cytogen stock being held in escrow; all rights to the two products revert to Advanced Magnetics (2/19) |
Dyax Corp. (DYAX) |
Genzyme Corp. (GENZ) | Terminated a four-year-old joint venture to commercialize DX-88 in hereditary angioedema | Dyax will regain full worldwide ownership and $17M in cash from Genzyme (2/21) |
Globe Laboratories Inc.* |
Chemokine Therapeutics Corp. (Canada; TSX:CTI) |
Chemokine terminated deal from 2003 deal under which Globe was performing chemokine-based research on a contract basis | As part of the deal Globe sold certain assets (laboratory equipment, leasehold improvements) to CTC for C$0.38M; CTC hired most Globe employees (1/9) |
ImClone Systems Inc. (IMCL) |
UCB SA (FSE:UNC) | ImClone backed out of development deal for the cancer drug CDP-791 | The deal was signed in the summer of 2005 (2/6) |
Orphan Therapeutics LLC* |
PDL BioPharma Inc. (PDLI) |
They ended deal under which PDL had rights to the Phase III agent terlipressin (Lucassin) | The move followed results from a trial in type 1 hepatorenal syndrome; Orphan regained rights to the product (12/19) |
Progen Industries Ltd. (Australia; PGLA) |
Medigen Biotechnology Corp. (Taiwan) | Progen is getting back all rights to PI-88, removing a 15% royalty obligation to Medigen | Progen surrendered its 19.9% equity stake in Medigen and will issue 500,000 shares to Medigen and pay $235,000 upon executing the agreement (1/16) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
NYSE = New York Stock Exchange. |